Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNL-NM-APRG006
- Development stage
- Preclinical
- Lead developer
- Genencell
- Modality
- Small Molecules
01
Overview
GNL-NM-APRG006 is a natural product-based drug candidate under development by the South Korean biopharmaceutical company Genencell. It is being investigated for the treatment of hepatitis. As a natural product medicine (천연물 의약품), the drug is derived from biological sources, although the specific botanical origin and molecular mechanism of action have not been publicly disclosed. The candidate is part of Genencell's pipeline of natural product therapeutics, which includes treatments for viral infections and inflammatory diseases. Development is currently focused on establishing efficacy and safety within the South Korean clinical landscape.
Beyond the preview
Go deeper on GNL-NM-APRG006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNL-NM-APRG006.